" class="no-js "lang="en-US"> Sobi - Medtech Alert
Wednesday, August 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Sobi | Pharmtech Focus

Sobi

About Sobi

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, our revenue amounted to SEK 15.3 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Related Story

Mergers & Aquisitions

 Sobi to Acquire CTI BioPharma | MTA

Sobi to Acquire CTI BioPharma

May 10 2023

CTI BioPharma, a commercial biopharmaceutical company focused on the development and commercialization of novel targeted […]

Diseases

 ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma | PTF

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma

December 21 2022

ADC Therapeutics SA and Swedish Orphan Biovitrum AB (Sobi) has announced the European Commission (EC) […]

Appointments

 Sobi Continues the R&D Transformation - Anders Ullman Appointed New Head of R&D | Pharmtech Focus

Sobi Continues the R&D Transformation - Anders Ullman Appointed New Head of R&D

December 13 2021

Anders Ullman, M.D., Ph.D., currently a member of the Board of Directors of Sobi, will […]